Evaluation of neurotransmitters involved in the anxiolytic and panicolytic effect of the aqueous fraction of Paullinia cupana (guaraná) in elevated T maze  by Rangel, Marcel P. et al.
358
ISSN 0102-695X
DOI 10.1590/S0102-695X2013005000024
Received 4 Dec 2012
Accepted 22 Jan 2013
Available online 5 Mar 2013
Revista Brasileira de Farmacognosia
Brazilian Journal of Pharmacognosy
23(2): 358-365, Mar./Apr. 2013 Evaluation of neurotransmitters involved 
in the anxiolytic and panicolytic effect of 
the aqueous fraction of Paullinia cupana 
(guaraná) in elevated T maze
Marcel P. Rangel,1 João Carlos P. de Mello,2 Elisabeth A. Audi*,1
1Departamento de Farmacologia e Terapêutica, Universidade Estadual de Maringá, 
Brazil,
2Departamento de Farmácia, Universidade Estadual de Maringá, Brazil.
Abstract: This study investigated the effects of repeatedly administration of an 
aqueous fraction of Paullinia cupana Kunth, Sapindaceae (guaraná) seeds (8 mg/
kg) on rats submitted to the elevated T-maze, model of generalized anxiety and panic 
disorders. The selective serotonin reuptake inhibitor paroxetine (3 mg/kg), was 
used as a positive control. To evaluate possible neurotransmissions involvement, 
ineffective doses of metergoline (3 mg/kg - non-selective serotonin receptor 
antagonist), sulpiride (20 mg/kg - non-selective dopaminergic receptor antagonist) 
or ketamine (0.125 mg/kg - non-selective glutamate receptor antagonist) were 
acutely administered in association with the aqueous fraction of P. cupana. Both 
aqueous fraction and paroxetine decrease the inhibitory avoidance latencies of the 
elevated T-maze, indicating anxiolytic effect and increased one-way escape latencies 
from the open arm of the elevated T-maze, indicating a panicolytic effect. The pre-
treatment with metergoline, sulpiride and ketamine blocked the anxiolytic effect of 
aqueous fraction. The panicolytic effect of aqueous fraction was blocked by both 
metergoline and sulpiride. These results show that the serotonergic, dopaminergic 
and glutamatergic neurotransmission systems are involved in anxiolytic effect 
promoted by aqueous fraction, whereas only the serotonergic and the dopaminergic 
neurotransmission systems are involved in the panicolytic effect promoted by 
aqueous fraction of P. cupana. The effects produced by paroxetine, were blocked 
only by metergoline, validating this experimental procedure.
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Introduction
 The anxiety disorder comprises distinct 
pathological conditions such as generalized anxiety 
disorder (GAD), panic disorder (PD), social phobias 
(SP) and posttraumatic stress disorder (PSD) (Kessler et 
al., 2005). GAD is the most common of all psychiatric 
disorders leading to great suffering, being defi ned as a 
generalized vague and unpleasant feeling (Andrade & 
Gorestein, 1998). PD is defi ned by the presence of recurrent 
panic attacks that consist of a feeling of fear or intense 
discomfort, accompanied by physical symptoms that 
abruptly start (Craske & Barlow, 1993). Selective serotonin 
reuptake inhibitors (SSRI) are considered treatment of fi rst 
choice due to its high effi cacy and tolerability (Yacubian 
& Minutentag, 2001), however, they have limitations as 
a delayed onset of effects, an initial worsening of anxiety 
symptoms (Blier & Montigny, 1999) and resistance occurs 
in approximately 30% of patients (Thase & Rush, 1995). 
Those limitations of therapeutically show that the search 
for new therapeutic strategies is necessary.
 It is estimated that Brazil has the greatest plant 
biodiversity in the world (Guerra & Nodari, 2001), and 
Paullinia cupana Kunth (guaraná) it belongs to the 
Sapindaceae family and is popularly known as guaraná 
(Henman, 1982), its pharmacological actions have been a 
target of interest for pharmaceutical laboratories. Its seeds 
containing high concentrations of xanthenes and traces 
of theophylline and theobromine, high concentrations of 
polyphenols and saponins which contain catechins and 
other condensed tannins (Benowitz, 1990). Popularly, 
several effects, as antidiarrheal (Basile et al., 2005), 
antioxidant (Mattei et al., 1998) and stimulant of central 
nervous system (CNS) (Carlini, 2003), are attributed to 
the extract of the dried guaraná seeds by the high content 
of methylxanthines, especially caffeine (Antonelli-
Ushiroba et al., 2004). Confi rming this CNS stimulant 
effect popularly attributed, a semi-purifi ed fraction 
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obtained from guaraná seed fraction, called PEA showed 
improvement in performance and memory speed (Otobone 
et al., 2005), produced antidepressant-like effects in rats 
(Otobone et al., 2007) and panicolytic effect similar to the 
one produced by the antidepressant paroxetine, in animals 
subjected to elevated T-maze (ETM), this effect was 
evident participation of the neurotransmitters serotonin 
and dopamine (Roncon et al., 2010). 
 Although the neurotransmitters as noradrenaline 
(NA), serotonin (5-HT) and dopamine (DA) have been 
the focus of research in developing treatments related to 
anxiety disorders for a long time (Cansado et al., 2012), 
new therapeutic approaches require the search for new 
treatments on different transmissions. Thus, the glutamate 
system is emerging as a component of a new generation of 
antidepressants (Berman et al., 2000). Ketamine (KET), 
a glutamatergic N-methyl-D-aspartate antagonist receptor, 
showed an antidepressant effect in rodents in the forced 
swimming test (Mathew et al., 2005). Also, sub-therapeutic 
dose of KET provides a rapid antidepressant response in 
patients resistant to treatment (Murrough, 2012). This study 
evaluated if the FAQ has anxiolytic and panicolytic effects 
in rats submitted to ETM test, and if the serotoninergic, 
dopaminergic and glutamatergic neurotransmissions are 
involved in these effects.
Materials and Methods
Plant material
 The Paullinia cupana Kunth, Sapindaceae 
(guaraná) seeds were collected in city of Alta Floresta, 
State of Mato Grosso, Brazil. They were then dried, 
identified and pulverized in a hammer mill (Tigre ASN-5). 
Identification was carried out by Dr. Cássia Sakuragui. A 
voucher plant specimen (#HUEM9065) was deposited in 
the herbarium of the State University of Maringá.
Extraction
 The extract was prepared from the guaraná 
seeds (1000 g) by turbolysis using an acetone:water 
(7:3; v/v) extractor solution in proportion of 10% (w/v). 
After removal of the organic solvent, the remaining solid 
material was lyophilized (EBPC-crude lyophilized extract, 
patent pending PI0006638-9). Then, 158 g of the EBPC 
was partitioned with ethyl acetate (10×0.5 L), resulting in 
an aqueous fraction (FAQ: 114 g) and ethyl acetate fraction 
(PEA: 44 g).
Drugs
 FAQ, Paroxetine (PAR, SSRI; IPCA Laborat; 
99.1%), Metergoline (MET, Sigma; 5-HT receptor 
antagonist; ≥98%), Sulpiride (SUL, Sigma; non-selective 
dopaminergic receptor antagonist; ≥98%) were solubilized 
in saline solution (0.9% NaCl) containing 2% Tween 80, 
and Ketamine (KET, non-selective glutamate receptor 
antagonist, Virbac®) injectable solution, was used from 
the ampule. The control group was treated with only the 
vehicle (VEH; 0.9% NaCl plus 2% Tween 80).
Animals
 Male Wistar rats (230-250 g) at constant room 
temperature (22-23 °C) under a 12 h light-dark cycle 
with free access to food and water were used in the 
experiments. The experiments were performed between 
13 and 18 h. The procedures adopted were approved 
by the State University of Maringá Ethics Committee 
(107/2011), and followed the recommended guidelines 
for Biomedical Research Involving Animals (CIMS), 
Geneva, 1985.
Apparatus
 The ETM was constructed of wood and had three 
arms of equal dimensions (50 × 12 cm). One arm, enclosed 
by 40 cm high walls, was perpendicular to two opposed 
open arms. The entire apparatus was positioned 50 cm 
above the floor. Locomotion was measured in a circular 
wooden arena, 70 cm in diameter, with 30 cm high walls. 
Luminosity at the level of the maze arms and at the center 
of the circular arena was 60 lux.
Behavioral tests
 One day before the test, each animal was pre-
exposed to one of the open arms of the ETM for 30 min. 
A wooden barrier mounted between the central area of the 
maze and the proximal end of the arm isolated it from the 
rest of the ETM. It has been shown that such pre-exposure 
to the open arm makes the escape task a more sensitive 
measure of the effects of panicolytic drugs.
 After 24 h, the ETM test was initiated by the 
inhibitory avoidance task. For this, each animal was placed 
at the distal end of the enclosed arm of the ETM facing 
the intersection. The time taken by the rat to leave this 
arm with all four paws was recorded (baseline latency). 
This measurement was repeated in two subsequent trials 
(avoidance 1 and 2) at 30 s intervals. Thirty seconds after 
the avoidance trials, the rats were placed at the end of the 
open arm they had been previously exposed to, and the 
latency to leave this arm with all four paws was recorded 
in three consecutive trials (one-way escape 1, 2, and 3) 
at 30 s intervals. A cut-off time of 300 s was established 
for the avoidance and escape latencies. In acute treatment, 
manipulation of the animal is made 5 min in the lap of a 
researcher and 5 min of habituation in the box after three 
days of their arrival at the laboratory. On day 4, animals 
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were handled the same way again and confined to one of 
the open arms of ETM for 30 min. Thirty seconds after 
being tested in the ETM, each animal was placed in the 
circular arena for 5 min to evaluate their locomotion. The 
total distance traveled was analyzed by a video tracking 
system (Ethovision; Noldus, Holland).
Treatment
 Treatment 1 - Determination the FAQ effect
 The animals were treated by gavage (i.g.) for 21 
days with PAR (3 mg/kg), FAQ (8 mg/kg) or VEH and 
submitted to the behavioral tests 30 min after this last 
treatment.
 Treatment 2 - Dose response curve of ketamine
 The animals were treated with a single dose 
of KET (0.0625, 0.125 and 0.25 mg/kg) or VEH by 
intraperitoneal route (i.p.) and submitted to the behavioral 
tests 30 min after this treatment.
 Treatment 3 - Associates treatment
 The animals were treated for 21 days with PAR (3 
mg/kg), FAQ (8 mg/kg) or VEH (i.g.) and only in the 21th 
day of treatment, the animals were acutely pretreated with 
the VEH or antagonists (i.p.), and then treated with PAR 
(3 mg/kg), FAQ (8 mg/kg) or VEH (i.g.) 5 min later. They 
were submitted to the behavioral tests 30 min after the last 
treatment.
Statistical analysis
 Repeated-measure analyses of variance 
(RMANOVA) were used to analyze both avoidance 
and escape data. The treatments were considered as the 
independent factors and the trials (baseline, avoidance 1 
and 2 and escape 1-3) as the repeated measures. When 
appropriate, one-way ANOVA followed by the post hoc 
Duncan’s multiple comparison tests, were used. Locomotion 
data were analyzed by one-way ANOVAs followed by the 
post hoc Duncan’s multiple comparison tests. Differences 
between groups were considered significant if p<0.05.
Results and Discussion
 Antidepressant drugs of different classes have 
been successfully used for the treatment of anxiety 
disorder subtypes, including GAD (Kim et al., 2006) 
and PD (Pollack & Doyle, 2003). However, SSRI show 
delay in the onset of therapeutic effect and initial worse 
of anxiety symptoms, specially observed in PD patients 
(Zanoveli et al., 2007). Therefore, the development of new 
therapeutic strategies with a faster onset of action and fewer 
adverse effects has been the focus of research developed 
by industry and academic. Guaraná is popularly used as 
anorectic, nootropic and aphrodisiac (Henman, 1982; 
O’Dea, 2003; Oliveira et al., 2005). Animal studies using a 
semi-purified fraction obtained from an extract of guaraná 
seeds (PEA), already demonstrated improved performance 
and memory speed, antidepressant-like effects (Otobone et 
al., 2005; 2007) and antipanic-like effects in rats (Roncon 
et al., 2010). 
 This study evaluated the effects of FAQ on rats 
in the ETM test, an animal model developed to assess 
defensive behaviors related to specific subtypes of anxiety 
disorders, as GAD and PD, and PAR was chosen as positive 
control in the study, because as the first SSRI licensed by 
the Food and Drug Administration and has proven effective 
in treating PD. 
 Figure 1 show the effects of repeated treatment 
with control group (VEH), PAR (3 mg/kg), or FAQ (8 mg/
kg) in the ETM, and (Figure 1A) showed significant effect 
on the avoidance to FAQ at baseline (*p=0.02), avoid 1 
Figure 1. Means±SEM of administration (21 days, i.g.) of control group (VEH), PAR (3 mg/kg) or FAQ (8 mg/kg) on inhibitory 
avoidance (panel A) and one-way escape latencies (panel B) in the ETM test (n=9-10). *p<0.05, compared to the VEH.
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(*p=0.007) and 2 (*p=0.001) latencies, and PAR showed 
significant effect on the avoidance at baseline (*p=0.02), 
avoid 1 (*p=0.01) and 2 (*p=0.002) latencies, compared to 
control group (VEH), indicating the anxiolytic-like effect 
for FAQ and PAR. For the escape trial (Figure 1B), showed 
that FAQ increased escape 1 (*p=0.001) and 2 (*p=0.003) 
latencies, and that PAR significantly increased escape 
1 (*p=0.001), 2 and 3 (*p=0.01) latencies compared to 
the control group, indicating the panicolytic-like effect. 
One-way ANOVA did not show significant differences in 
distances traveled under the different treatments compared 
to control group (Table 1).
Table 1. Distance traveled in meters (m) in the circular arena by 
rats repeatedly treated with FAQ or PAR.
Drug (mg/kg) Distance traveled (m)
VEH 19.12±1.54
PAR (3) 17.44±1.46
FAQ (8) 20.28±1.54
Data presented as means±SEM. n=9-10. p>0.05 compared to control 
group (VEH) after repeated administration (i.g.) with FAQ and PAR.
 In the combined treatment to evaluation of the 
neurotransmitters involved in the effect of FAQ, Figure 
2 shows the results observed in the ETM test for the 
pretreatment of the VEH or MET (3 mg/kg), to evaluate 
the involvement of serotonergic neurotransmission in the 
effect of FAQ. For the inhibitory avoidance trial (Figure 
2A), RMANOVA showed that FAQ significantly reduce the 
latencies of avoid 1 (*p<0.05), and 2 (*p=0.002), and PAR 
significantly reduce avoid 1 (*p<0.05), and 2 (*p=0.006) 
latencies compared to control group. For the escape trial 
(Figure 2B), showed that FAQ increased escape 1 and 2 
(*p=0.001) latencies. PAR significantly increased escape 
1 (*p=0.001), 2 and 3 (*p<0.05) latencies compared to the 
control group. These results confirm the anxiolytic and the 
panicolytic effect of FAQ observed in treatment 1. 
 MET blocked the anxiolytic effect produced 
by FAQ, as can be seen by the significant differences in 
avoid 2 ($p=0.001) latencies between the MET+FAQ and 
the VEH+FAQ groups. Furthermore, MET blocked the 
anxiolytic effect produced by PAR, as can be seen by the 
significant differences in avoid 2 (#p=0.001) latencies 
between the MET+PAR and the VEH+PAR groups (Figure 
Figure 2. Means±SEM of acute administration (i.p.) of MET or SUL in rats treated (21 days, i.g.) with VEH, PAR (3 mg/kg) or FAQ 
(8 mg/kg) on inhibitory avoidance (A and C panel) and one-way escape (B and D panel) latencies in the ETM test (n=9-13). *p<0.05, 
compared to the control group (VEH+VEH), #p<0.05, compared to the VEH+PAR, $p<0.05, compared to the VEH+FAQ groups.
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2A). MET blocked the panicolytic effect produced by FAQ, 
as can be seen by the significant differences in escape 1 
and 2 ($p=0.001) latencies between the MET+FAQ and 
the VEH+FAQ groups. Furthermore, MET blocked the 
panicolytic effect produced by PAR, as can be seen by the 
significant differences in escape 1(#p=0.001), 2 (#p=0.002) 
and 3 (#p=0.008) latencies between the MET+PAR and the 
VEH+PAR groups (Figure 2B). For the positive control, 
PAR, the blockage of anxiolytic and panicolitc by MET was 
expected, and validate the experimental model, according 
to the literature, this effect was due to the blockade of 
postsynaptic receptors by sensitization chronic exerted by 
compound (Humphrey et al., 1986; Ellis et al., 1991). The 
blockage of anxiolytic and panicolitic effect of FAQ by 
MET suggests that possible involvement of serotonergic 
neurotransmission in the anxiolytic and panicolytic effect 
of the FAQ.
 Although SSRI are considered the first-
choice treatment for PD, other neurotransmitters, 
are also important in the etiology and treatment of 
GAD and depression (Goodnick et al., 1998). DA is a 
neurotransmitter between these, and drugs capable of 
blocking the reuptake of DA demonstrate efficacy in 
the treatment of PD (Gebhart et al., 2008) and improve 
symptoms of GAD (Reis et al., 2004). 
 Figure 2 shows the results observed 
in the ETM for the pretreatment of the VEH or 
SUL (20 mg/kg), to evaluate the involvement of 
dopaminergic neurotransmission in the effect of 
FAQ. For the inhibitory avoidance trial (Figure 2C), 
FAQ significantly reduce avoid 1 (*p=0.003) and 2 
(*p=0.001) latencies, and PAR significantly reduce 
avoid 1 (*p=0.02) and 2 (*p=0.002) latencies, compared 
to control group, indicating an anxiolytic effect. SUL 
blocked the anxiolytic effect produced by FAQ can 
be seen by the significant differences in avoid 1 and 
2 ($p=0.001) latencies between the SUL+FAQ and the 
VEH+FAQ groups. For the escape trial (Figure 2D) 
showed that FAQ increased escape 1, 2 (*p=0.001) 
and 3 (*p=0.009), and PAR significantly increased 
escape 1, 2 and 3 (*p=0.001) latencies compared to 
control group, indicating a panicolytic effect. SUL also 
blocked the panicolytic effect produced by FAQ, as can 
be seen by the significant differences in escape 1, 2 and 
3 ($p=0.001) latencies between the SUL+FAQ and the 
VEH+FAQ groups, but did not blocked the effect of 
PAR both the avoidance and escape (p>0.05) latencies, 
suggesting the possible involvement of dopaminergic 
neurotransmission in the anxiolytic and panicolytic 
effect of the FAQ.
  In the analysis of glutamatergic 
neurotransmission, it was necessary to make the dose 
response curve of KET, showed in Figure 3. For the 
inhibitory avoidance trial (Figure 3A), the anxiogenic 
effect appeared in the ETM test in animals treated 
with a single dose of KET (0.25 mg/kg), on the 
avoidance at baseline (*p=0.001), avoid 1 (*p<0.05) 
and 2 (*p=0.004) latencies compared to control group. 
Anxiogenic effect also has been reported in the study 
with animals pretreated with a single dose of KET and 
submitted to the elevated plus maze (Silvestre et al., 
1997). For the escape trial (Figure 3B), KET there was 
no significant effect (p>0.05). A one way ANOVA did 
not show significant differences in locomotor activity 
(Table 2), being so established a sub effective dose of 
KET (0.125 mg/kg) for evaluation the involvement of 
glutamate in the FAQ effect.
 Figure 4 shows the results observed in 
the ETM test for the pretreatment of the VEH or 
KET (0.125 mg/kg), to evaluate the involvement of 
glutamatergic neurotransmission in the effect of FAQ. 
For the inhibitory avoidance trial (Figure 4A), showed 
that FAQ significantly reduce avoid 1 (*p<0.05), 2 
(*p=0.001) latencies, and PAR significantly reduce 
avoid 1 (*p<0.05), 2 (*p=0.001) latencies, compared 
to control group, indicating an anxiolytic effect. 
KET blocked the anxiolytic effect produced by FAQ, 
as can be seen by the significant differences in avoid 1 
Figure 3. Means±SEM of acute administration (i.p.) of VEH or KET (0.0625, 0.125 or 0.25 mg/kg) on inhibitory avoidance (panel 
A) and one-way escape latencies (panel B) in the ETM test (n=6-8). *p<0.05, compared to the VEH.
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($p<0.05) and avoid 2 ($p=0.007) latencies between the 
KET+FAQ and the VEH+FAQ groups, but not blocked 
the effect of PAR on avoid (p>0.05) latencies. For the 
escape trial (Figure 4B), showed that both FAQ as PAR 
increased escape 1, 2 (*p=0.001) and 3 (*p<0.05) latencies 
compared to the control group indicating a panicolytic 
effect. KET not blocked the panicolytic effect of PAR and 
FAQ on the escape (p>0.05) latencies, showing that this 
effect promoted by FAQ in ETM test does not mediated 
by glutamatergic receptors. In agreement with our results, 
the literature does not report effective use of glutamatergic 
drugs in PD (Harvey & Shahid, 2011).
Table 2. Distance traveled in meters (m) in the circular arena by 
rats treated acutely with KET.
Drug (mg/kg) Distance traveled (m)
VEH 12.42±1.58
KET (0.0625) 11.17±1.37
KET (0.125) 14.83±1.37
KET (0.25) 13.61±1.37
Data presented as means±SEM. n=6-8. p>0.05 compared to control group 
(VEH) after acute treatment (i.p.) with KET.
 The glutamatergic neurotransmission is related 
to GAD, because glutamate is the major excitatory 
neurotransmitter in the CNS, and its blockade can cause 
symptoms of schizophrenia (Parsons et al., 2007), this 
involvement of the glutamate neurotransmitter was 
evident in the results, where KET blocked the anxiolytic 
effect shown by the FAQ. One way ANOVA did not show 
significant differences in distance traveled under these 
different treatments compared to the control group (Table 3). 
 Our results with PAR and FAQ confirm the need 
for a latency period until the onset of the therapeutic, 
antidepressant compounds as well as, data from the 
literature indicate that period of about 21 days due to 
the need for changes in the adaptive receivers serotonin 
receptors, located in the raphe nucleus as well as the 
raising of different post-synaptic receptors (Pineyro & 
Blier, 1999).
Table 3. Distance in meters (m) traveled by rats in the circular 
arena following combined drug administration.
Drug (mg/kg) Distance traveled (m)
VEH + VEH 18.86±1.01
VEH + PAR (3) 19.96±1.10
VEH + FAQ (8) 17.25±1.01
MET (3) + VEH 16.96±1.16
MET (3) + PAR (3) 18.58±1.16
MET (3) + FAQ (8) 16.54±0.97
SUL (20) + VEH 18.36±1.14
SUL (20) + PAR (3) 17.06±1.08
SUL (20) + FAQ (8) 17.48±0.95
KET (0.125) + VEH 17.51±0.96
KET (0.125) + PAR (3) 16.02±0.96
KET (0.125) + FAQ (8) 16.08±0.96
Data presented as means±SEM. n=7-13. p>0.05 compared to control 
group (VEH). Acutely administered VEH, MET, SUL or KET (i.p.) 
followed by repeated administration VEH, FAQ or PAR (i.g.).
 In conclusion, the present study demonstrated 
that FAQ is active orally, that it produces anxiolytic 
and panicolytic effect on rats in the ETM test, and that 
the serotonergic, dopaminergic and glutamatergic 
neurotransmissions are involved on the anxyolitic effect and 
that the serotonergic and dopaminergic neurotransmission 
are involved in the panicolytic effect. These results suggest 
that FAQ could be a useful drug in the treatment of mood 
disorders such as GAD and PD.
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